Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (CC): Updated analysis of stage II disease from the AVANT phase III randomized trial by the GERCOR group

被引：0
|
作者：
De Gramont, A. [1 ]
Henriques, J. [2 ]
Baruch, B. [3 ,4 ]
Kim, T. W. [5 ]
Martinez-Villacampa, M. [6 ]
Gallego-Plazas, J. [7 ]
Cervantes, A. [8 ]
Shim, K. [9 ]
Jonker, D. J. [10 ]
Guerin-Meyer, V. [11 ]
Mineur, L. [12 ]
Banzi, M. [13 ]
Dewdney, A. [14 ]
Dejthevaporn, T. Sirisingha [15 ]
Bloemendal, H. J. [16 ]
Roth, A. D. [17 ]
Thompson, P. [18 ]
Moehler, M. [19 ]
Aranda Aguilar, E. [20 ]
Andre, T. [21 ]
机构：
[1] Inst Hosp Franco Britannique, Dept Med Oncol, Levallois Perret, France
[2] Univ Hosp Besancon, INSERM, UMR 1098, Methodol & Qual Life Unit Oncol, Besancon, France
[3] Rabin Med Ctr, Davidoff Canc Ctr, Dept Oncol, Petah Tiqwa, Israel
[4] Sackler Sch Med, Tel Aviv, Israel
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Inst Catala Oncol IDIBELL Hospitalet, Dept Med Oncol, Barcelona, Spain
[7] Gen Univ Elche Hosp, Dept Med Oncol, Elche, Spain
[8] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain
[9] Lakeridge Hlth RS McLaughlin Durham Reg Canc Ctr, Med Oncol, Oshawa, ON, Canada
[10] Univ Ottawa, Ottawa Hosp Res Inst, Div Med Oncol, Dept Med, Ottawa, ON, Canada
[11] Inst Cancerol Ouest Paul Papin, Dept Gastroenterol & Hepatol, Angers, France
[12] Inst St Catherine, Radiotherapy & Oncol GI & Liver, Avignon, France
[13] Azienda Osped Arcispedale Santa Maria Nuova IRCCS, Oncol Unit, Reggio Emilia, Italy
[14] Weston Pk Hosp, Canc Res Ctr, Dept Oncol, Sheffield, S Yorkshire, England
[15] Ramathibodi Hosp, Med Oncol, Bangkok, Thailand
[16] Meander Med Ctr, Dept Internal Med Med Oncol, Amersfoort, Netherlands
[17] HUG, Dept Oncol, Digest Tumour Unit, Geneva, Switzerland
[18] Auckland City Hosp, Dept Med Oncol, Auckland, New Zealand
[19] Univ Med Mainz, Dept Med Oncol, Mainz, Germany
[20] Univ Hosp Reina Sofia, Dept Med Oncol, Cordoba, Spain
[21] Hop St Antoine, Dept Med Oncol, Paris, France
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
553P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial
    Wang, Xin Shelley
    Shi, Qiuling
    Bhadkamkar, Nishin A.
    Cleeland, Charles S.
    Garcia-Gonzalez, Araceli
    Aguilar, Jonathan R.
    Heijnen, Cobi
    Eng, Cathy
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2019, 58 (04) : 662 - 671
  • [42] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
    Saltz, Leonard B.
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Cassidy, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
  • [43] Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
    Kotaka, Masahito
    Yamanaka, Takeharu
    Yoshino, Takayuki
    Manaka, Dai
    Eto, Tetsuya
    Hasegawa, Junichi
    Takagane, Akinori
    Nakamura, Masato
    Kato, Takeshi
    Munemoto, Yoshinori
    Nakamura, Fumitaka
    Bando, Hiroyuki
    Taniguchi, Hiroki
    Gamoh, Makio
    Shiozawa, Manabu
    Saji, Shigetoyo
    Maehara, Yoshihiko
    Mizushima, Tsunekazu
    Ohtsu, Atsushi
    Mori, Masaki
    ESMO OPEN, 2018, 3 (03)
  • [44] Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer:: A planned safety analysis in 1,864 patients
    Schmoll, Hans-Joachim
    Cartwright, Thomas
    Tabernero, Josep
    Nowacki, Marek P.
    Figer, Arie
    Maroun, Jean
    Price, Timothy
    Lim, Robert
    Van Cutsem, Eric
    Park, Young-Suk
    McKendrick, Joseph
    Topham, Claire
    Soler-Gonzalez, Gemma
    de Braud, Filipo
    Hill, Mark
    Sirzen, Florin
    Haller, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (01) : 102 - 109
  • [45] Real-world tolerance and outcomes to oxaliplatin-based adjuvant chemotherapy for stage III colon cancer - Does dose intensity matter?
    Yoon, Robert
    Wilkinson, Kate
    Gabriel, Gabriel
    Kaadan, Nasreen
    Roberts, Tara
    Lim, Stephanie
    Ray, Asghari
    Lee, Cheok Soon
    Chua, Wei
    Ng, Weng
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 132 - 133
  • [46] Using T stage to predict outcomes of adjuvant oxaliplatin (OX)-based chemotherapy (CT) in stage III colon cancer (CC): An ACCENT pooled analysis.
    Cohen, Romain
    Raeisi, Morteza
    Yothers, Greg
    Schmoll, Hans-Joachim
    Haller, Daniel G.
    Bachet, Jean-Baptiste
    Chibaudel, Benoist
    Wolmark, Norman
    Yoshino, Takayuki
    Goldberg, Richard M.
    Kerr, Rachel
    Lonardi, Sara
    George, Thomas J.
    Shmueli, Einat Shacham
    Sharara, Lama
    Andre, Thierry
    Shi, Qian
    De Gramont, Aimery
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Planned Safety Analysis of the ACTS-CC 02 Trial: A Randomized Phase III Trial of S-1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High-Risk Stage III Colon Cancer
    Kusumoto, Tetsuya
    Sunami, Eiji
    Ota, Mitsuyoshi
    Yoshida, Kazuhiro
    Sakamoto, Yoshiyuki
    Tomita, Naohiro
    Maeda, Atsuyuki
    Mochizuki, Izumi
    Okabe, Michio
    Kunieda, Katsuyuki
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Sugihara, Kenichi
    CLINICAL COLORECTAL CANCER, 2018, 17 (02) : E153 - E161
  • [48] A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
    Takahashi, Takao
    Sunami, Eiji
    Kusumoto, Tetsuya
    Ota, Mitsuyoshi
    Sakamoto, Yoshiyuki
    Tomita, Naohiro
    Maeda, Atsuyuki
    Tejima, Jin
    Okabe, Michio
    Tanaka, Chihiro
    Yamauchi, Junichiro
    Itabashi, Michio
    Kotake, Kenjiro
    Takahashi, Keiichi
    Baba, Hideo
    Boku, Narikazu
    Aiba, Keisuke
    Ishiguro, Megumi
    Morita, Satoshi
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [49] A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial
    Andre, T.
    Van Cutsem, E.
    Schmoll, H.
    Tabernero, J.
    Clarke, S.
    Moore, M. J.
    Cunningham, D.
    Cartwright, T. H.
    Hecht, J. R.
    Rivera, F.
    Im, S.
    Bodoky, G.
    Salazar, R.
    Maindrault-Goebel, F.
    Shmueli, E.
    Bajetta, E.
    Makrutzki, M.
    Shang, A.
    De Gramont, A.
    Hoff, P. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [50] A comparison of oxaliplatin-based adjuvant chemotherapy versus improved nodal sampling for stage II colon cancer: Cost-effectiveness and survival
    Chen, SL
    Sim, MS
    Bilchik, AJ
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 41 - 42
12345